Delivering Resveratrol on the Buccal Mucosa Using Mucoadhesive Tablets: A Potential Treatment Strategy for Inflammatory Oral Lesions

Martins, Isadora Conde Ferreira; Raposo, Nádia Rezende Barbosa; Mockdeci, Hanny Reis; Polonini, Hudson; Ferreira, Adriana; Fabri, Gisele Maria Campos; Chaves, Maria das Graças Afonso Miranda

doi:10.2174/1567201814666170726102558

Cited by 12 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, resveratrol has relatively small molecular weight and uncharged at physiological pH, allowing passive diffusion across the buccal mucosa [17,20]. There is some literature data about mucoadhesive pharmaceutical formulations containing resveratrol, such as lozenge [18], mucoadhesive film [21] or tablets [22].…”

Section: Introductionmentioning

confidence: 99%

Cyclodextrin as Functional Carrier in Development of Mucoadhesive Tablets Containing Polygoni cuspidati Extract with Potential for Dental Applications

Paczkowska-Walendowska

Szymańska

Winnicka

et al. 2021

Pharmaceutics

View full text Add to dashboard Cite

Polygoni cuspidati root is a resveratrol-rich source with anti-inflammatory, angiogenic and neuroprotective effects. The raw material was standardized for the content of resveratrol, for which there is a special justification for administration within the oral mucosa. To improve the solubility of resveratrol and to assure its high content in plant material, an ultrasound-assisted extraction method was applied. The addition of cyclodextrin was found to increase the extraction efficiency of resveratrol (from 13 to 297 µg per 1 g of plant material in case of 50% ethanol extracts) and enhanced its antioxidant activity as compared to pure Polygoni cuspidati extract/resveratrol. Cyclodextrin plays the role of a functional extract regarding technological properties (increasing the extraction of resveratrol from the extract, improving mucoadhesive properties). Therefore, the aim of this study was to develop mucoadhesive tablets containing combinations of the Polygoni cuspidati extract with a cyclodextrin carrier for buccal delivery. The tests sequentially included extract preparation and characterization of its physical and biological properties and then formulation studies with a broad description of the prototype properties. The test results indicate that cyclodextrin increases the efficiency of resveratrol extraction from Polygoni cuspidati rhizome, which is a rich source of resveratrol, and its extract enclosed in a mucoadhesive tablet guarantees prolonged action at the site of administration.

show abstract

Section: Introductionmentioning

confidence: 99%

Cyclodextrin as Functional Carrier in Development of Mucoadhesive Tablets Containing Polygoni cuspidati Extract with Potential for Dental Applications

Paczkowska-Walendowska

Szymańska

Winnicka

et al. 2021

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Resveratrol-loaded mucoadhesive formulations have been proposed for the prevention and treatment of inflammatory conditions of the oral cavity [ 22 ]. RES-loaded mucoadhesive tablets were reported to exert a local effect, rather than a systemic one, in a porcine model which was deemed more desirable for local inflammatory conditions such as oral mucositis, lichen planus, erythema multiforme, nicotinic stomatitis, and recurrent aphthous stomatitis [ 22 ]. Mucoadhesive cyclodextrin and xanthan gum-based buccal formulations have also been investigated as potential RES delivery systems.…”

Section: Resultsmentioning

confidence: 99%

A Brief Updated Review of Advances to Enhance Resveratrol’s Bioavailability

2021

View full text Add to dashboard Cite

Resveratrol (RES) has a low bioavailability. This limitation was addressed in an earlier review and several recommendations were offered. A literature search was conducted in order to determine the extent of the research that was conducted in line with these recommendations, along with new developments in this field. Most of the identified studies were pre-clinical and confirmed the heightened activity of RES analogues compared to their parent compound. Although this has provided additional scientific kudos for these compounds and has strengthened their potential to be developed into phytopharmaceutical products, clinical trials designed to confirm this increased activity remain lacking and are warranted.

show abstract

“…The drug delivery system was designed to hold the drug on the oral surface and avoid the drug entering the systemic circulation. 89 …”

Section: Discussionmentioning

confidence: 99%

Evolution of Drug Delivery Systems for Recurrent Aphthous Stomatitis

Suharyani¹,

Mohammed²,

Muchtaridi³

et al. 2021

DDDT

View full text Add to dashboard Cite

Recurrent aphthous stomatitis (RAS) is a disease marked by painful oral lesions on the buccal and labial mucosa or tongue. Drug delivery systems (DDS) for RAS include topical forms that manage wound healing, cover the ulcer, and relieve the associated pain. DDS targeting the oral mucosa face a major challenge, especially the short residence times in the mouth due to the effect of “saliva wash-out”, which continually removes the drug. The objective of this review is to study the development of preparation forms and delivery systems of various types and preparations that have been used for RAS management from 1965 until February 2020. There are 20 types of DDS for RAS which were discussed in 62 articles. The preparations were classified into 4 preparation forms: liquid, semi-solid, solid, and miscellaneous. In addition, the ultimate DDS for RAS preparations is the semi-solid forms (41.94%), which include 5 types of DDS are gel, paste, patch, cream, and ointment. This preparation was developed into new preparation form (11.29%), such as adhesive alginates, dentifrice, OraDisc, membranes, bioresorbable plates, pellicles, and gelosomes. Generally, the mucosal drug delivery system is the method of choice in RAS treatment because the ulcer is commonly located in the oral mucosa. In conclusion, these preparations are designed to improve drug delivery and drug activity for the treatment of RAS ulcers. Moreover, almost all of these DDS are topical preparations that use various types of mucoadhesive polymers to increase both residence time in the oral mucosa and pain relief in RAS treatment.

show abstract

Delivering Resveratrol on the Buccal Mucosa Using Mucoadhesive Tablets: A Potential Treatment Strategy for Inflammatory Oral Lesions

Cited by 12 publications

References 0 publications

Cyclodextrin as Functional Carrier in Development of Mucoadhesive Tablets Containing Polygoni cuspidati Extract with Potential for Dental Applications

Cyclodextrin as Functional Carrier in Development of Mucoadhesive Tablets Containing Polygoni cuspidati Extract with Potential for Dental Applications

A Brief Updated Review of Advances to Enhance Resveratrol’s Bioavailability

Evolution of Drug Delivery Systems for Recurrent Aphthous Stomatitis

Contact Info

Product

Resources

About